x
Filter:
Filters applied
- Opioids
- Atayee, Rabia SRemove Atayee, Rabia S filter
- CNSRemove CNS filter
Keyword
- 6-MAM1
- 6-monoacetylmorphine1
- central nervous system1
- dimethylamylamine1
- DMAA1
- ELISA1
- enzyme-linked immunosorbent assay1
- EtG1
- ethyglucuronide1
- FDA1
- Food and Drug Administration1
- gas chromatography/mass spectrometry1
- GC-MS1
- LC-MS/MS1
- liquid chromatography/tandem mass spectrometry1
- MDPV1
- NSAID1
- PCP1
- POCT1
- PPI1
- TCA1
- THC1
- THCV1
- UDT1
Opioids
1 Results
- Review
Clinical Interpretation of Urine Drug Tests: What Clinicians Need to Know About Urine Drug Screens
Mayo Clinic ProceedingsVol. 92Issue 5p774–796Published online: March 18, 2017- Karen E. Moeller
- Julie C. Kissack
- Rabia S. Atayee
- Kelly C. Lee
Cited in Scopus: 86Urine drug testing is frequently used in clinical, employment, educational, and legal settings and misinterpretation of test results can result in significant adverse consequences for the individual who is being tested. Advances in drug testing technology combined with a rise in the number of novel misused substances present challenges to clinicians to appropriately interpret urine drug test results. Authors searched PubMed and Google Scholar to identify published literature written in English between 1946 and 2016, using urine drug test, screen, false-positive, false-negative, abuse, and individual drugs of abuse as key words.